Molecular profiling of metastatic renal cell carcinoma treated with ipilimumab-nivolumab
by Christina Black | Nov 19, 2021
Immune and cancer testis antigen landscape in sarcoma
by Christina Black | Nov 19, 2021
Diverse RNA expression patterns of T cell priming markers in various solid tumors and their clinical implication
by Christina Black | Sep 17, 2021
PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer
by OmniSeq Staff | Dec 3, 2020
Follow Us on Twitter
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz